Phase II Study of Combination Ruxolitinib (INCB018424) with Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer protocol # TBCRC 039

Administered By

Awarded By

Contributors

Start/End

  • December 14, 2018 - September 1, 2022